STOML2抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Mouse brain tissue, Rat heart tissue, Rat brain tissue lysates, Primary antibody: P09676(STOML2 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P09676(STOML2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

STOML2 (Stomatin-like protein 2) is a member of the stomatin protein family, characterized by its conserved stomatin domain. It is ubiquitously expressed in eukaryotic cells, primarily localized in cellular membranes, mitochondria, and lysosomes. STOML2 plays roles in regulating ion channel activity, membrane trafficking, and cellular signaling. Recent studies highlight its involvement in cancer progression, where overexpression is observed in malignancies like colorectal cancer, glioblastoma, and hepatocellular carcinoma, correlating with enhanced proliferation, invasion, and metastasis. It interacts with key oncogenic pathways, including EGFR and ERK/MAPK signaling, and modulates mitochondrial function, influencing apoptosis and metabolic reprogramming.

STOML2 antibodies are essential tools for investigating its biological functions and clinical relevance. These antibodies enable detection of STOML2 expression levels via Western blotting, immunohistochemistry, and immunofluorescence, aiding in studies of its subcellular localization and disease associations. Researchers also utilize STOML2 antibodies to explore its potential as a diagnostic or prognostic biomarker and to evaluate therapeutic strategies targeting STOML2 in preclinical models. Validation of antibody specificity is critical, as cross-reactivity with homologous stomatin family members (e.g., STOML1/3) may occur. Overall, STOML2 antibodies contribute to unraveling its pathophysiological mechanisms, particularly in cancer and metabolic disorders. (Word count: 243)